Half Year 2025 Valneva SE Earnings Call Transcript
Key Points
- Valneva SE (INRLF) achieved significant year-over-year revenue growth, reaching close to EUR100 million in the first half of 2025.
- The company maintained a strong cash position of over EUR160 million, indicating effective cash management and reduced operating cash burn.
- Valneva SE (INRLF) secured additional marketing authorizations for its chikungunya vaccine, IXCHIQ, in the UK, Brazil, and Europe, expanding its market reach.
- The Lyme disease vaccine candidate, VALOR, is progressing as planned, with Pfizer aiming for regulatory submissions in 2026.
- The company reported positive Phase III pediatric safety and immunogenicity results for IXCHIQ, reinforcing its potential in the market.
- Valneva SE (INRLF) reported an operating loss of EUR16.8 million in the first half of 2025, compared to an operating profit in the previous year.
- The company experienced adverse foreign currency fluctuations, impacting revenues by EUR500,000.
- Research and development expenses increased, driven by costs related to the Shigella vaccine candidate.
- The company faced temporary restrictions on its chikungunya vaccine, IXCHIQ, due to safety concerns, impacting market uptake.
- Valneva SE (INRLF) anticipates an acceleration of R&D costs in the second half of 2025, which could further impact financial performance.
Thank you, operator. Hello, and thank you for joining us to discuss Valneva's first half 2025 results and corporate update. It's my pleasure to welcome you today. In addition to our press release and analyst presentation, you can find our consolidated financial results for the 6 months ended June 30, 2025, which were published earlier today available within the Financial Reports section on our Investor website.
I'm joined today by Valneva's CEO, Thomas Lingelbach; and our CFO, Peter Buhler, who will provide an overview and update on our business as well as our key financial results for the first half. There will be an analyst Q&A session at the conclusion of the prepared remarks. Before we begin, I'd like to remind listeners that during this presentation, we will be making forward-looking statements, which are subject to certain risks and uncertainties that could cause actual results to differ materially from those expressed or implied by these forward-looking statements.
You can find additional information about
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
